Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study

Leonardi, M. C.; Pepa, M.; Zaffaroni, M.; Vincini, M. G.; Luraschi, R.; Vigorito, S.; Morra, A.; Dicuonzo, S.; Mazzola, G. C.; Gerardi, M. A.; Zerella, M. A.; Cante, D.; Petrucci, E.; Borzi, G.; Marrocco, M.; Chieregato, M.; Iadanza, L.; Lobefalo, F.; Valenti, M.; Cavallo, A.; Russo, S.; Guernieri, M.; Malatesta, T.; Meaglia, I.; Liotta, M.; Palumbo, I.; Marcantonini, M.; Mezzenga, E.; Falivene, S.; Arrichiello, C.; Barbero, M. P.; Ivaldi, G. B.; Catalano, G.; Vidali, C.; Giannitto, C.; Ciabattoni, A.; Meattini, I.; Aristei, C.; Orecchia, R.; Cattani, F.; Jereczek-Fossa, B. A.

doi:10.1177/03008916231196801

This study quantified the incidental dose to the first axillary level (L1) in locoregional treatment plan for breast cancer. Eighteen radiotherapy centres contoured L1-L4 on three different patients (P1,2,3), created the L2-L4 planning target volume (single centre planning target volume, SC-PTV) and elaborated a locoregional treatment plan. The L2-L4 gold standard clinical target volume (CTV) along with the gold standard L1 contour (GS-L1) were created by an expert consensus. The SC-PTV was then replaced by the GS-PTV and the incidental dose to GS-L1 was measured. Dosimetric data were analysed with Kruskal-Wallis test. Plans were intensity modulated radiotherapy (IMRT)-based. P3 with 90° arm setup had statistically significant higher L1 dose across the board than P1 and P2, with the mean dose (Dmean) reaching clinical significance. Dmean of P1 and P2 was consistent with the literature (77.4% and 74.7%, respectively). The incidental dose depended mostly on L1 proportion included in the breast fields, underlining the importance of the setup, even in case of IMRT.

Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study / Leonardi M.C.; Pepa M.; Zaffaroni M.; Vincini M.G.; Luraschi R.; Vigorito S.; Morra A.; Dicuonzo S.; Mazzola G.C.; Gerardi M.A.; Zerella M.A.; Cante D.; Petrucci E.; Borzi G.; Marrocco M.; Chieregato M.; Iadanza L.; Lobefalo F.; Valenti M.; Cavallo A.; Russo S.; Guernieri M.; Malatesta T.; Meaglia I.; Liotta M.; Palumbo I.; Marcantonini M.; Mezzenga E.; Falivene S.; Arrichiello C.; Barbero M.P.; Ivaldi G.B.; Catalano G.; Vidali C.; Giannitto C.; Ciabattoni A.; Meattini I.; Aristei C.; Orecchia R.; Cattani F.; Jereczek-Fossa B.A.. - In: TUMORI. - ISSN 0300-8916. - ELETTRONICO. - (2023), pp. 0-0. [10.1177/03008916231196801]